Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 22037470)

1.

Identifying polyglutamine protein species in situ that best predict neurodegeneration.

Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, Segal M, Yang XW, Masliah E, Thompson LM, Muchowski PJ, Weisgraber KH, Finkbeiner S.

Nat Chem Biol. 2011 Oct 30;7(12):925-34. doi: 10.1038/nchembio.694. Erratum in: Nat Chem Biol. 2012 Mar;8(3):318.

2.

PolyQ disease: misfiring of a developmental cell death program?

Blum ES, Schwendeman AR, Shaham S.

Trends Cell Biol. 2013 Apr;23(4):168-74. doi: 10.1016/j.tcb.2012.11.003. Epub 2012 Dec 8. Review.

4.

Expanded polyglutamine stretches lead to aberrant transcriptional regulation in polyglutamine diseases.

Shimohata T, Onodera O, Tsuji S.

Hum Cell. 2001 Mar;14(1):17-25. Review.

PMID:
11436350
5.

Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?

Takahashi T, Katada S, Onodera O.

J Mol Cell Biol. 2010 Aug;2(4):180-91. doi: 10.1093/jmcb/mjq005. Epub 2010 Apr 21. Review.

6.
7.

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.

Lunkes A, Trottier Y, Fagart J, Schultz P, Zeder-Lutz G, Moras D, Mandel JL.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1013-9. Review.

8.

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.

Takeuchi T, Popiel HA, Futaki S, Wada K, Nagai Y.

Curr Med Chem. 2014;21(23):2575-82. Review.

PMID:
24533807
9.

Polyglutamine expansion diseases: failing to deliver.

Morfini G, Pigino G, Brady ST.

Trends Mol Med. 2005 Feb;11(2):64-70. Review.

PMID:
15694868
10.

Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Wetzel R.

J Mol Biol. 2012 Aug 24;421(4-5):466-90. doi: 10.1016/j.jmb.2012.01.030. Epub 2012 Jan 27. Review.

11.

Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.

Kubota H, Kitamura A, Nagata K.

Methods. 2011 Mar;53(3):267-74. doi: 10.1016/j.ymeth.2010.12.035. Epub 2010 Dec 30. Review.

PMID:
21195182
12.

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.

Sakahira H, Breuer P, Hayer-Hartl MK, Hartl FU.

Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16412-8. Epub 2002 Aug 20. Review.

13.

[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].

Nagai Y.

Rinsho Shinkeigaku. 2009 Nov;49(11):913-6. Review. Japanese.

PMID:
20030247
14.

Nuclear accumulation of polyglutamine disease proteins and neuropathology.

Havel LS, Li S, Li XJ.

Mol Brain. 2009 Jul 3;2:21. doi: 10.1186/1756-6606-2-21. Review.

15.

Polyglutamine and neurodegeneration: structural aspects.

Masino L.

Protein Pept Lett. 2004 Jun;11(3):239-48. Review.

PMID:
15182225
16.
17.

Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.

Matos CA, de Macedo-Ribeiro S, Carvalho AL.

Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Review.

PMID:
21740957
18.

Toxic proteins in neurodegenerative disease.

Taylor JP, Hardy J, Fischbeck KH.

Science. 2002 Jun 14;296(5575):1991-5. Review.

PMID:
12065827
19.

Polyglutamine diseases: a transcription disorder?

Okazawa H.

Cell Mol Life Sci. 2003 Jul;60(7):1427-39. Review.

PMID:
12943229
20.

Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity.

Pennuto M, Palazzolo I, Poletti A.

Hum Mol Genet. 2009 Apr 15;18(R1):R40-7. doi: 10.1093/hmg/ddn412. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk